Atea PharmaceuticalsAVIR
About: Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Employees: 75
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2.29% more ownership
Funds ownership: 65.02% [Q1] → 67.31% (+2.29%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
3% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 37
6% less funds holding
Funds holding: 111 [Q1] → 104 (-7) [Q2]
15% less capital invested
Capital invested by funds: $221M [Q1] → $188M (-$33.4M) [Q2]
35% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 20
94% less call options, than puts
Call options by funds: $297K | Put options by funds: $5.37M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Morgan Stanley Matthew Harrison 58% 1-year accuracy 14 / 24 met price target | 92%upside $6.88 | Equal-Weight Upgraded | 13 Aug 2024 |
Financial journalist opinion
Based on 4 articles about AVIR published over the past 30 days
